natgillin/translations-raw huggingface dataset:
C12 1.70 (1.49, 1.94)
C12 1,70 (1,49; 1,94)
C12 10.17 (8.73-11.85)
C12 10,17 (8,73-11,85)
C12hr (nM)
C12h (nM)
C208 - C216 (QUEST-1 and QUEST-2;
C208 - C216 (QUEST-1 i QUEST-2;
C212 (Phase 3)
(Faza 3)
C24 0.31 (0.25, 0.38)
C24 0,31 (0,25; 0,38)
C24 0.41 (0.28, 0.59)
C24 0,41 (0,28; 0,59)
C24 0.69 (0.54, 0.88)
C24 0,69 (0,54; 0,88)
C24 0.77 (0.61, 0.99)
C24 0,77 (0,61; 0,99)
C24 0.80 (0.55, 1.16)
C24 0,80 (0,55; 1,16)
C24 0.80 (0.70, 0.91)
C24 0,80 (0,70; 0,91)
C24 0.84 (0.71, 0.99)
C24 0,84 (0,71; 0,99)
C24 0.86 (0.79, 0.93)
C24 0,86 (0,79; 0,93)
C24 0.90 (0.82, 0.99)
C24 0,90 (0,82; 0,99)
C24 0.91 (0.82, 1.01)
C24 0,91 (0,82; 1,01)
C24 0.91 (0.87, 0.96)
C24 0,91 (0,87; 0,96)
C24 0.92 (0.18, 1.05)
C24 0,92 (0,18; 1,05)
C24 0.92 (0.83, 1.02)
C24 0,92 (0,83; 1,02)
C24 0.93 (0.84, 1.03)
C24 0,93 (0,84; 1,03)
C24 0.93 (0.87, 1.00)
C24 0,93 (0,87; 1,00)
C24 0.93 (0.88, 0.98)
C24 0,93 (0,88; 0,98)
C24 0.94 (0.87, 1.02)
C24 0,94 (0,87; 1,02)
C24 0.95 (0.87, 1.04)
C24 0,95 (0,87; 1,04)
C24 0.96 (0.86, 1.08)
C24 0,96 (0,86; 1,08)
C24 0.97 (0.89, 1.06)
C24 0,97 (0,89; 1,06)
C24 0.97 (0.92, 1.02)
C24 0,97 (0,92; 1,02)
C24 0.98 (0.84, 1.13)
C24 0,98 (0,84; 1,13)
C24 0.98 (0.88, 1.09)
C24 0,98 (0,88; 1,09)
C24 1.00 (0.93, 1.07)
C24 1,00 (0,93; 1,07)
C24 1.03 (0.91, 1.17)
C24 1,03 (0,91; 1,17)
C24 1.03 (0.92, 1.17)
C24 1,03 (0,92; 1,17)
C24 1.04 (0.97, 1.12)
C24 1,04 (0,97; 1,12)
C24 1.05 (0.97, 1.14)
C24 1,05 (0,97; 1,14)
C24 1.07 (0.99, 1.16)
C24 1,07 (0,99; 1,16)
C24 1.10 (0.96, 1.26)
C24 1,10 (0,96; 1,26)
C24 1.11 (1.00, 1.23)
C24 0,21 (0,17; 0,26)
C24 1.12 (0.97, 1.30)
C24 1,12 (0,97; 1,30)
C24 1.14 (0.95, 1.36)
C24 1,14 (0,95; 1,36)
C24 1.15 (1.02, 1.29)
C24 1,19 (1,13; 1,25)
C24 1.16 (1.09, 1.23)
C24 1,16 (1,09; 1,23)
C24 1.17 (1.02, 1.34)
C24 1,17 (1,02; 1,34)
C24 1.19 (1.13, 1.25)
C24 1,19 (1,13; 1,25)
C24 1.20 (0.98, 1.47)
C24 1,20 (0,98; 1,47)
C24 1.20 (1.15, 1.26)
C24 1,20 (1,15; 1,26)
C24 1.21 (1.03, 1.43)
C24 1,21 (1,03; 1,43)
C24 1.22 (0.99, 1.51)
C24 1,22 (0,99; 1,51)
C24 1.22 (1.02, 1.45)
C24 1,22 (1,02; 1,45)
C24 1.23 (1.09, 1.40)
C24 1,24 (1,10; 1,39)
C24 1.23 (1.13, 2.34)
C24 1,15 (1,02; 1,29)
C24 1.24 (1.10, 1.39)
C24 0,89 (0,78; 1,01)
C24 1.29 (1.18, 1.41)
C24 1,29 (1,18; 1,41)
C24 1.31 (1.11, 1.55)
C24 1,31 (1,11; 1,55)
C24 1.31 (1.12, 1.53)
C24 1,31 (1,12; 1,53)
C24 1.39 (1.25, 1.56)
C24 1,39 (1,25; 1,56)
C24 1.53 (1.43, 1.63)
C24 1,53 (1,43; 1,63)
C24 1.77 (1.40, 2.24)
C24 1,77 (1,40; 2,24)
C24 1.82 (1.39, 2.39)
Cmax 6,24 (4,42; 8,81)
C24 1.89 (1.37, 2.60)
C24 1,89 (1,37; 2,60)
C24 2.21 (1.98, 2.47)
C24 2,21 (1,98; 2,47)
C24 2.38 (2.19, 2.60)
C24 2,38 (2,19; 2,60)
C24 2.78 (2.48, 3.11)
Cmax 4,59 (3,70; 5,69)
C24 3.39 (2.82, 4.09)
C24 3,39 (2,82; 4,09)
C24 6.45 (5.51, 7.54)
dizoproksilfumaratom (fiksna
C24  32% (Complex binding to polyvalent ions)
C24  32% (stvaranje kompleksa s polivalentnim ionima)
C24  38% (induction of UGT1A1 and CYP3A enzymes)
C24  38% (indukcija enzima UGT1A1 i CYP3A)
C24  39% (Complex binding to polyvalent ions)
C24  39% (stvaranje kompleksa s polivalentnim ionima)
C24  56% (Complex binding to polyvalent ions)
C24  56% (stvaranje kompleksa s polivalentnim ionima)
c: 3 morning, 3 evening d: 3 morning, 4 evening
c: 3 ujutro, 3 navečer d: 3 ujutro, 4 navečer
C: Giving the injection
Davanje injekcije
C: observed as uncommon in prevention of atherothrombotic events in patients after an ACS (following percutaneous coronary intervention)
C: uočeno kao manje često kod prevencije aterotrombotičkih događaja u bolesnika nakon akutnog koronarnog sindroma (nakon perkutanog koronarnog zahvata)
C: observed as uncommon in prevention of atherothrombotic events in patients after an ACS (following percutaneous coronary intervention)
C: uočeno kao manje često kod prevencije aterotrombotičkih događaja u bolesnika nakon akutnog koronarnog sindroma (nakon perkutanog koronarnog zahvata).
C: observed as uncommon in prevention of atherothrombotic events in patients after an ACS (following percutaneous coronary intervention)
C: uočeno kao manje često kod prevencije aterotrombotskih događaja u bolesnika nakon akutnog koronarnog sindroma (nakon perkutanog koronarnog zahvata)
c: subjects < 75 kg received 100 µg/week peginterferon alfa-2b and subjects ≥ 75 kg received 150 µg/week peginterferon alfa-2b . d: Ribavirin dosing was 800 mg for patients < 60 kg, 1,000 mg for patients 60-75 kg, and 1,200 mg for patients > 75 kg.
c: ispitanici teški < 75 kg primali su 100 μg lijeka peginterferon alfa 2-b na tjedan, a ispitanici teški ≥ 75 kg primali su 150 μg lijeka peginterferon alfa-2b na tjedan. d: doza ribavirina iznosila je 800 mg za bolesnike teške < 60 kg, 1000 mg za bolesnike teške 60-75 kg, te 1200 mg za bolesnike teže od 75 kg.
c: subjects < 75 kg received 100 µg/week peginterferon alfa-2b and subjects ≥ 75 kg received 150 µg/week peginterferon alfa-2b . d: Ribavirin dosing was 800 mg for patients < 60 kg, 1,000 mg for patients 60-75 kg, and 1,200 mg for patients > 75 kg.
c: ispitanici teški < 75 kg primali su 100 μg lijeka peginterferon alfa-2b na tjedan, a ispitanici teški ≥ 75 kg primali su 150 μg lijeka peginterferon na tjedan. d: doza lijeka ribavirin iznosila je 800 mg za bolesnike teške < 60 kg, 1000 mg za bolesnike teške 60-75 kg, te 1200 mg za bolesnike teže od 75 kg.
c: subjects < 75 kg received 100 µg/week peginterferon alfa-2b and subjects ≥ 75 kg received 150 µg/week peginterferon alfa-2b . d: Ribavirin dosing was 800 mg for patients < 60 kg, 1,000 mg for patients 60-75 kg, and 1,200 mg for patients > 75 kg.
c: ispitanici teški <75 kg primali su 100 μg lijeka peginterferon alfa-2b na tjedan, a ispitanici teški ≥ 75 kg primali su 150 μg peginterferon alfa-2b na tjedan. d: doza lijeka Ribavirin iznosila je 800 mg za bolesnike teške <60 kg, 1000 mg za bolesnike teške 60-75 kg, te 1200 mg za bolesnike teže od 75 kg.
c: subjects < 75 kg received 100 µg/week pegylated interferon alfa-2b and subjects ≥ 75 kg received 150 µg/week pegylated interferon alfa-2b. d: ribavirin dosing was 800 mg for patients < 60 kg, 1,000 mg for patients 60-75 kg, and 1,200 mg for patients > 75 kg.
c: ispitanici teški < 75 kg primali su 100 μg pegiliranog interferona alfa-2b na tjedan, a ispitanici teški ≥ 75 kg primali su 150 μg pegiliranog interferona alfa-2b na tjedan. d: doza ribavirina iznosila je 800 mg za bolesnike teške < 60 kg, 1000 mg za bolesnike teške 60-75 kg, te 1200 mg za bolesnike ≥ 75 kg.
C: To mix the recommended number of REYATAZ oral powder sachets with food such as applesauce or yogurt in a small container:
C: Za miješanje preporučenog broja vrećica REYATAZ oralnog praška s hranom kao što je kašica od jabuke ili jogurt u malom spremniku:
CA 91320 USA
CA 91320 SAD
CA 92056 USA
CA 92056 SAD
CA 94710
Berkeley, CA 94710 SAD
CA = continuous abstinence rate; CI = confidence interval; NRT=Nicotine replacement therapy patch
CA (engl. continuous abstinence) = stopa neprekidne apstitencije; CI = interval pouzdanosti; NRT= flaster nikotinske zamjenske terapije
CA was defined as the proportion of all subjects treated who did not smoke (not even a puff of a cigarette) from Week 9 through Week 52 and did not have an exhaled CO measurement of > 10 ppm.
CA je definirana kao stopa svih liječenih ispitanika koji nisu pušili (čak niti jedan dim cigarete) između 9. i 52. tjedna i u kojih izmjerena količina CO u izdisaju nije bila > 10 ppm.
CA Wk 9-52
9.-52. tjedan
CA* wk 13-24
CA* 13.-24. tjedan
CA* wk 15-24
CA* tjedan 15-24 32,1
CA* wk 21-52
CA* tjedan 21-52 27,0
CA* wk 9-12
CA* 9.-12. tjedan
CA* wk 9-52
CA* 9.-52. tjedan
Ca-DTPA (Trisodium calcium diethylenetriaminepentaacetate) or
Ca-DTPA (trinatrij kalcij dietilen-triamin-pentaacetat) ili
Ca-DTPA (Trisodium calcium diethylenetriaminepentaacetate) or
Ca-DTPA (Trinatrijev kalcij dietilenetriaminpentaacetat) ili
Ca-DTPA (Trisodium calcium diethylenetriaminepentaacetate) or
Ca-DTPA (trinatrijev kalcijev dietilentriaminpentaacetat) ili
Ca-DTPA (Trisodium calcium diethylenetriaminepentaacetate) or Ca-EDTA (Calcium disodium ethylenediaminetetraacetate)
Ca-DTPA (Kalcijev trinatrij-dietilen-triamin-pentaacetat) ili Ca-EDTA (Kalcijev dinatrij-etilendiamin-tetraacetat)
Ca-EDTA (Calcium disodium ethylenediaminetetraacetate)
Ca-EDTA (kalcij dinatrij etilen-diamin-tetraacetat)
Ca-EDTA (Calcium disodium ethylenediaminetetraacetate)
Ca-EDTA (Kalcijev dinatrij etilenediamintetraacetat)
Ca-EDTA (Calcium disodium ethylenediaminetetraacetate)
Ca-EDTA (kalcijev dinatrijev etilendiamintetraacetat)
CA225006: This randomised study in patients with metastatic colorectal cancer who had received initial combination treatment with oxaliplatin plus fluoropyrimidine for metastatic disease compared the combination of cetuximab and irinotecan (648 patients) with irinotecan alone (650 patients).
CA225006: Ovo randomizirano ispitivanje kod bolesnika s metastatskim kolorektalnim karcinomom koji su na početku liječenja metastatske bolesti primili kombinaciju oksaliplatina i fluoropirimidina uspoređivalo je kombinaciju cetuksimaba i irinotekana (648 bolesnika) i samo irinotekana (650 bolesnika).
CA225025: This randomised study in patients with metastatic colorectal cancer who had received prior oxaliplatin-, irinotecan- and fluoropyrimidine-based treatment for metastatic disease compared the addition of cetuximab as a single agent to best supportive care (BSC) (287 patients) with best supportive care (285 patients).
CA225025: Ovo randomizirano ispitivanje u bolesnika s metastatskim kolorektalnim karcinomom koji su za liječenje metastatske bolesti prethodno primali terapiju baziranu na oksaliplatinu, irinotekanu i fluoropirimidinu uspoređivalo je dodatak cetuksimaba kao samostalnog lijeka najboljoj suportivnoj terapiji (BSC) (287 bolesnika) s najboljom suportivnom terapijom (285 bolesnika).
cabamazepine, phenytoin (medicines to treat epilepsy or other illness). warfarin, dipyridamole, phenprocoumon, low-dose acetylsalicylic acid (blood thinning medicines).
karbamazepin, fenitoin (lijekovi za liječenje epilepsije i drugih bolesti) varfarin, dipiridamol, fenprokumon, niske doze acetilsalicilne kiseline (lijekovi za razrjeđivanje krvi)
cabamazepine, phenytoin (medicines to treat epilepsy or other illness). warfarin, dipyridamole, phenprocoumon, low-dose acetylsalicylic acid (blood thinning medicines).
karbamazepin, fenitoin (lijekovi za liječenje epilepsije i drugih bolesti). varfarin, dipiridamol, fenprokumon, niske doze acetilsalicilne kiseline (lijekovi za razrjeđivanje krvi).
Cabazitaxel AUC: ↑ 1.3-fold
Kabazitaksel AUC: ↑ 1,3 puta
Cabazitaxel is eliminated primarily via liver metabolism.
Kabazitaksel se primarno eliminira metabolizacijom u jetri.
Cabazitaxel is minimally excreted through the kidney.
Kabazitaksel se minimalno izlučuje putem bubrega.
Cabazitaxel should not be used during breast-feeding.
Kabazitaksel se ne smije koristiti tijekom dojenja.
Cabazitaxel works by blocking the ability of cancer cells to break down their internal ‘skeleton’ that allows them to divide and multiply.
Kabazitaksel djeluje inhibirajući sposobnost stanica raka da razgrađuju svoj vlastiti unutarnji "kostur" koji im omogućuje diobu i umnožavanje.
Cabergoline
kabergolin
cabergoline lisuride, pergolide: risk of vasoconstriction and increase in blood pressure.
kabergolinom lizuridom i pergolidom: zbog rizika od vazokonstrikcije i povišenja krvnog tlaka.
CABG post-operative safety studies
Ispitivanja sigurnosti primjene nakon operacije ugradnje arteriokoronarne premosnice
CABG-related bleeding: In PLATO, 42% of the 1584 patients (12% of cohort) who underwent coronary artery bypass graft (CABG) surgery had a PLATO Major Fatal/Life-threatening bleeding with no difference between treatment groups.
Krvarenje povezano s CABG: u studiji PLATO, 42% od 1584 bolesnika (12% kohorte) koji su bili podvrgnuti operaciji aortokoronarne premosnice (CABG) imali su PLATO veliko fatalno/krvarenje koje ugrožava život bez razlike između liječenih skupina.
CABOMETYX 20 mg film-coated tablets are yellow, round with no score, and identified with “XL” on one side and “20” on the other side.
CABOMETYX 20 mg filmom obložene tablete su žute, okrugle bez ureza, s oznakom “XL” s jedne strane i “20” s druge strane.
CABOMETYX 20 mg film-coated tablets cabozantinib
CABOMETYX 20 mg filmom obložene tablete kabozantinib
CABOMETYX 40 mg film-coated tablets cabozantinib
CABOMETYX 40 mg filmom obložene tablete kabozantinib
CABOMETYX 60 mg film-coated tablets cabozantinib
CABOMETYX 60 mg filmom obložene tablete kabozantinib
Cabometyx 60 mg film-coated tablets EU/1/16/1136/005
CABOMETYX 60 mg filmom obložene tablete EU/1/16/1136/005
Cabometyx cabozantinib
Cabometyx kabozantinib
Cabometyx can only be obtained with a prescription and treatment should be started by a doctor who has experience in using cancer medicines.
Lijek Cabometyx izdaje se samo na recept, a terapiju lijekom mora započeti liječnik s iskustvom u primjeni lijekova za liječenje raka.
Cabometyx contains the active substance cabozantinib.
Lijek Cabometyx sadrži djelatnu tvar kabozantinib.
Cabometyx has been investigated in one main study involving 658 adults with advanced renal cell carcinoma that had got worse despite treatment with a VEGF inhibitor.
Lijek Cabometyx ispitivan je u okviru jednog glavnog ispitivanja provedenog na 658 odraslih osoba s uznapredovalim karcinomom bubrežnih stanica koji se pogoršao unatoč liječenju inhibitorom VEGF-a.
CABOMETYX is a cancer medicine that contains the active substance cabozantinib.
CABOMETYX je lijek protiv raka koji sadrži djelatnu tvar kabozantinib.
Cabometyx is a cancer medicine used to treat adults with advanced renal cell carcinoma (a type of kidney cancer) who have been previously treated with a type of cancer medicine called a ‘vascular endothelial growth factor (VEGF) inhibitor’.
Cabometyx je lijek za liječenje raka koji se primjenjuje za liječenje uznapredovaloga karcinoma bubrežnih stanica (vrste raka bubrega) u odraslih osoba koje su prethodno liječene vrstom lijeka za liječenje raka koji se naziva „inhibitor vaskularnog endotelnog čimbenika rasta (VEGF)”.
CABOMETYX is for oral use.
CABOMETYX je namijenjen za peroralnu primjenu.
CABOMETYX is indicated for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy
CABOMETYX je indiciran za liječenje uznapredovalog karcinoma bubrežnih stanica (engl. renal cell carcinoma, RCC) u odraslih, nakon prethodne terapije usmjerene na vaskularni endotelni faktor rasta (engl. vascular endothelial growth factor, VEGF) .
Cabometyx was shown to significantly improve the time these patients lived without their disease getting worse.
Pokazalo se da u tih bolesnika lijek Cabometyx znatno produljuje razdoblje bez pogoršanja bolesti.
Cabozantinib is not recommended for use in patients with severe hepatic impairment as safety and efficacy have not been established in this population.
Ne preporučuje se primjena kabozantiniba u bolesnika s teškim oštećenjem funkcije jetre jer sigurnost i djelotvornost lijeka nije utvrđena u ovoj populaciji.
Cabozantinib is not recommended for use in patients with severe hepatic impairment as safety and efficacy have not been established in this population.
Ne preporučuje se primjena kabozantiniba u bolesnika s teškim oštećenjem funkcije jetre jer sigurnost i djelotvornost u ovoj populaciji nisu ustanovljene.
Cabozantinib is not recommended for use in patients with severe renal impairment as safety and efficacy have not been established in this population.
Ne preporučuje se primjena kabozantiniba u bolesnika s teškim oštećenjem funkcije bubrega jer sigurnost i djelotvornost lijeka nije utvrđena u ovoj populaciji.
Cabozantinib is not recommended for use in subjects with severe hepatic impairment as safety and efficacy have not been established in this population.
Ne preporučuje se primjena kabozantiniba u bolesnika s teškim oštećenjem funkcije jetre jer sigurnost i djelotvornost lijeka nije utvrđena u ovoj populaciji.
Cabozantinib should be discontinued if hypertension is severe and persistent despite anti-hypertensive therapy and dose reduction of cabozantinib.
Ako je hipertenzija teška iperzistira unatoč primjeni antihipertenzivne terapije i smanjenju doze kabozantiniba, primjena kabozantiniba se mora prekinuti.
Cabozantinib should be discontinued if hypertension is severe and persistent despite anti-hypertensive therapy and dose reduction of cabozantinib.
Mora se prekinuti s primjenom kabozantiniba ako je hipertenzija teška i trajnaunatoč primjeni antihipertenzivne terapije i smanjenju doze kabozantiniba.
Cabozantinib should be discontinued in patients who develop an acute myocardial infarction or any other clinically significant arterial thromboembolic complication.
Mora se prestati s primjenom kabozantiniba u bolesnika u kojih se pojavi akutni infarkt miokarda ili bilo koja druga klinički značajna arterijske tromboembolijska komplikacija.
Cabozantinib should be discontinued in patients who develop an acute myocardial infarction or any other clinically significant arterial thromboembolic complication.
U bolesnika koji razviju akutni infarkt miokarda ili bilo koju drugu klinički značajnu arterijsku tromboembolijsku komplikaciju, primjena kabozantiniba mora se prekinuti.
Cabozantinib should be discontinued in patients who experience a GI perforation or a fistula that cannot be adequately managed .
U bolesnika u kojih se pojavi GI perforacija ili fistula koja se ne može odgovarajuće zbrinuti mora se prekinuti primjena kabozantiniba.
Cabozantinib should be discontinued in patients who experience a GI perforation or a GI or non-GI fistula.
Mora se prestati s primjenom kabozantiniba u bolesnika u kojih se pojavi gastrointestinalna perforacija ili pak gastrointestinalna il fistula izvan gastrointestinalnog sustava.
Cabozantinib should be restarted with a lower dose when PPES has been resolved to grade 1.
Kabozantinib se mora nastaviti u smanjenoj dozi kada se sindrom palmarno- plantarne eritrodizestezije smanji do 1. stupnja.
Cabozantinib was an inhibitor (IC50 = 7.0 μM), but not a substrate, of P-gp transport activities in a bi-directional assay system using MDCK-MDR1 cells.
Kabozantinib je bio inhibitor (IC50 = 7,0 μM), ali ne i supstrat, transportnih djelovanja P-glikoproteina (P-gp) u dvosmjernom sustavu testa uz uporabu MDCK-MDR1 stanica.
cachexia, diabetes mellitus, dyslipidaemia, hypercholesterolaemia, hyperglycaemia, hyperlipidaemia, hyperphagia, increased appetite, polydipsia, body fat disorder
kaheksija, diabetes mellitus, dislipidemija, hiperkolesterolemija, hiperglikemija, hiperlipidemija, hiperfagija, pojačan apetit, polidipsija, poremećaj masnog tkiva
Caecal lesions observed in some repeat-dose studies with rats, but not in monkeys, are not relevant for humans under normal conditions of administration.
Lezije cekuma primijećene u nekim istraživanjima pri ponovljenim dozama na štakorima, ali ne i na majmunima, nisu relevantne za čovjeka u propisanim uvjetima primjene.
CAELYX CARTON 20 mg/10 ml – 1 vial CAELYX CARTON 20 mg/10 ml – 10 vials
CAELYX KUTIJA 20 mg/10 ml – 1 bočica CAELYX KUTIJA 20 mg/10 ml – 10 bočica
CAELYX CARTON 50 mg/25 ml – 1 vial CAELYX CARTON 50 mg/25 ml – 10 vials
CAELYX KUTIJA 50 mg/25 ml – 1 bočica CAELYX KUTIJA 50 mg/25 ml – 10 bočica
Caelyx is administered intravenously at 20 mg/m2 every two-to-three weeks.
Caelyx se primjenjuje intravenski u dozi od 20 mg/m2 svaka dva do tri tjedna.
Caelyx is administered intravenously at a dose of 50 mg/m2 once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment.
Caelyx se primjenjuje intravenski u dozi od 50 mg/m2 jedanput svaka 4 tjedna, do progresije bolesti odnosno dok bolesnik podnosi liječenje.
Caelyx is also used to produce an improvement in your Kaposi’s sarcoma including flattening, lightening and even shrinkage of the cancer.
Caelyx se također primjenjuje za poboljšanje stanja kod Kaposijevog sarkoma gdje može izravnati, posvijetliti i čak smanjiti kancerozne promjene.
Caelyx is an antitumour agent.
Caelyx je antitumorski pripravak.
Caelyx is indicated:
Caelyx je indiciran:
Caelyx must be handled and disposed of in a manner consistent with that of other anticancer medicinal products in accordance with local requirements.
Način rukovanja lijekom Caelyx i njegovo uklanjanje moraju biti sukladni načinu rukovanja i uklanjanja drugih antitumorskih lijekova u skladu s lokalnim propisima.
Caelyx should not be used in children and adolescents, because it is not known how the medicine will affect them.
Caelyx se ne smije primjenjivati u djece i adolescenata, jer nije poznato kako će lijek djelovati na njih.
Caffeine (CYP1A2 substrate)
Kofein (supstrat za CYP1A2)
Caffeine 150 mg
Kofein 150 mg
caffeine AUC 1.26 (1.21-1.32) ↑ caffeine Cmax 1.12 (1.06-1.19) ↔ caffeine Cmin not studied
kofein AUC 1,26 (1,21-1,32) ↑ kofein Cmax 1,12 (1,06-1,19) ↔ kofein Cmin nije ispitano
Caffeine citrate can be either used without dilution or diluted in sterile solutions for infusion such as glucose 50 mg/ml (5%), or sodium chloride 9 mg/ml (0.9%) or calcium gluconate 100 mg/ml (10%) immediately after withdrawal from the ampoule (see section 6.6).
Kofein- citrat može se primijeniti bez razrjeđivanja ili razrijeđen sterilnom otopinom za infuziju, kao što je 5% otopina glukoze (50 mg/ml), 0,9% otopina natrijevog klorida (9 mg/ml) ili 10% otopina kalcijevog glukonata (100 mg/ml) neposredno nakon izvlačenja iz ampule (vidjeti dio 6.6).
Caffeine citrate is an ‘antagonist’ of adenosine, a substance that blocks the activity of some parts of the brain, including the part responsible for controlling breathing.
Kofeincitrat je "antagonist" adenozina, tvari koja inhibira aktivnost određenih dijelova mozga, uključujući dio odgovoran za kontrolu disanja.
Caffeine has a prolonged half-life in premature newborn infants and there is potential for accumulation which may necessitate monitoring infants treated for an extended period (see section 5.2).
Poluvijek kofeina je produljen u prerano rođene dojenčadi i postoji mogućnost njegova nakupljanja, zbog čega može biti nužno nadzirati dojenčad koja se liječi dulje vrijeme (vidjeti dio 5.2).
Caffeine is excreted into breast milk and readily crosses the placenta into the foetal circulation (see section 5.2).
Kofein se izlučuje u majčino mlijeko, dobro prolazi posteljicu i ulazi u fetalni krvotok (vidjeti dio 5.2).
Caffeine therapy reduced the rate of bronchopulmonary dysplasia [odds ratio (95%CI) 0.63 (0.52 to 0-76)] and improved the rate of survival without neurodevelopmental disability [odds ratio (95%CI) 0.77 (0.64 to 0.93)].
Terapija kofeinom smanjila je stopu bronhopulmonalne displazije [omjer šansi (95% CI) 0,63 (0,52 do 0-76)] i poboljšala stopu preživljenja bez neurorazvojnog invaliditeta [omjer šansi (95% CI) 0,77 (0,64 do 0,93)].
Caffeine: AUCinf: ↑ 4%
Kofein: AUCinf: ↑ 4
Caffeine: no dose adjustment required.
Kofein: nije potrebna prilagodba doze..
Caffeine’s main action is as a CNS stimulant.
Glavno djelovanje kofeina jest da je on stimulans središnjeg živčanog sustava.
Calcitonin Responsea
Odgovor kalcitoninaa
Calcium and vitamin D levels should be monitored.
Razine kalcija i vitamina D trebaju se pratiti.
Calcium and Vitamin D supplementation
Dodatak kalcija i vitamina D
Calcium and vitamin D supplementation should be withdrawn
Nadomjeske kalcija i vitamina D treba obustaviti
Calcium antagonists (c)
Antagonisti kalcija (c)
calcium carbonate antacid
antacid s s kalcijevim karbonatom/lamivudin
Calcium carbonate: Co-administration of calcium carbonate (single 1,500 mg dose) did not alter the pharmacokinetics of cinacalcet.
Kalcijev karbonat: Istodobna primjena kalcijeva karbonata (jednokratna doza do 1500 mg) ne mijenja farmakokinetiku sinakalceta.
calcium channel antagonists (e.g. felodipine, nifedipine, nicardipine); medicines used to correct heart rhythm (e.g. bepridil, systemic lidocaine, quinidine);
antagoniste kalcijevih kanala (npr. felodipin, nifedipin, nikardipin); lijekove za ispravljanje srčanog ritma (npr. bepridil, sistemski lidokain, kinidin);
CALCIUM CHANNEL BLOCKERS
ANTIMIKOBAKTERICI
calcium channel blockers
kalcijevih kanala u plazmi